Sanofi announced today that it signed a licensing agreement with Glenmark Pharmaceuticals S. A. (GPSA). This agreement covers the development and marketing GBR500, a new monoclonal antibody for the treatment of Crohn's disease and other chronic autoimmune diseases.
GBR500 just be a Phase I study in the United States in order to determine its optimal dose and was well tolerated with a good pharmacokinetic profile.
"There is still an important medical need for products that are better tolerated and more effective in the treatment of inflammatory diseases," said Dr. Elias Zerhouni, President Worldwide Research and Development at Sanofi. "Through its innovative approach, the GBR500 complete portfolio of Sanofi on the treatment of inflammatory diseases and could address the lack of treatments against inflammatory diseases for the benefit of patients."
GBR500 just be a Phase I study in the United States in order to determine its optimal dose and was well tolerated with a good pharmacokinetic profile.
"There is still an important medical need for products that are better tolerated and more effective in the treatment of inflammatory diseases," said Dr. Elias Zerhouni, President Worldwide Research and Development at Sanofi. "Through its innovative approach, the GBR500 complete portfolio of Sanofi on the treatment of inflammatory diseases and could address the lack of treatments against inflammatory diseases for the benefit of patients."